# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print on Tr	ma Parmanaa	(2)					,	·							
(Print or Type Responses)  1. Name and Address of Reporting Person* TERRELL JASON BRADLEY MD				2. Issuer Name and Ticker or Trading Symbol VOLITIONRX LTD [VNRX]      3. Date of Earliest Transaction (Month/Day/Year)     11/03-05:00/2021						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner X_Officer (give title below) Other (specify below)  Chief Medical Officer					
(Last) (First) (Middle) 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B															
		(Street)		4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)					_X_ For	6. Individual or Joint/Group Filing/Check Applicable Line)X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
AUSIIN (Ci	I, TX 7873	(State)	(Zip)				T 11 Y	- N D - 4			. ,	c D C			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye			ear) Exe	2A. Deemed 3. Transa Execution Date, if Code			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		ed 5. Amo Owned Transac (Instr. 3	Owned Following Reported Transaction(s) (Instr. 3 and 4)			wnership orm: B virect (D) O	Nature f Indirect eneficial wnership nstr. 4)	
Reminder:	Report on a	separate line for eac	h class of securities	II - Deri	ivati	ve Securi	ties Acqu	Persons withis form a currently vired, Disposed		ed to respo ntrol number ially Owned	nd unles			n SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)		ise (Month/Day/Year)		4. 5. Number of Transaction Derivative Code Securities		options, convertible securities  6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following	10. Ownership Form of Derivative Security: Direct (D)	Beneficia		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s (Instr. 4)	or Indirect (I) (Instr. 4)	
Stock Option (Right to Buy)	\$ 4	11/03- 05:00/2021		D <sub>(1)</sub>			25,000	04/15- 05:00/2017	04/15- 05:00/2022	Common Stock	25,000	(1)	0	D	
Stock Option (Right to Buy)	\$ 4	11/03- 05:00/2021		A <sup>(1)</sup>		25,000		04/15- 05:00/2017	04/15- 05:00/2026	Common Stock	25,000	(1)	25,000	D	
Stock Option (Right to Buy)	\$ 5	11/03- 05:00/2021		D <sup>(2)</sup>			50,000	03/30- 05:00/2018	03/30- 05:00/2023	Common Stock	50,000	(2)	0	D	
Stock Option (Right to Buy)	\$ 5	11/03- 05:00/2021		A <sup>(2)</sup>		50,000		03/30- 05:00/2018	03/30- 05:00/2027	Common Stock	50,000	(2)	50,000	D	
Stock Option (Right to Buy)	\$ 4	11/03- 05:00/2021		D <sup>(3)</sup>			50,000	01/23- 05:00/2019	01/23- 05:00/2024	Common Stock	50,000	(3)	0	D	
Stock Option (Right	\$ 4	11/03- 05:00/2021		A <sup>(3)</sup>		50,000		01/23- 05:00/2019	01/23- 05:00/2028	Common Stock	50,000	(3)	50,000	D	

## **Reporting Owners**

to Buy)

	Relationships					
Reporting Owner Name / Address	Director 10% Owner	Officer	Other			
	•					

TERRELL JASON BRADLEY MD 13215 BEE CAVE PARKWAY, SUITE 125 GALLERIA OAKS B		Chief Medical Officer	
AUSTIN, TX 78738			

#### **Signatures**

/s/ Jason Terrell MD	11/05-05:00/2021
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options (1) were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).
- The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options (2) were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).
- The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options (3) were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.